John A. Olson
YOU?
Author Swipe
View article: Author response: General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants
Author response: General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants Open
View article: Author response: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants
Author response: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants Open
View article: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants Open
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Though most people with CF have one or two copies of the ΔF508 mutation, there are hundreds of other dist…
View article: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants Open
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Though most people with CF have one or two copies of the ΔF508 mutation, there are hundreds of other dist…
View article: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants Open
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Though most people with CF have one or two copies of the ΔF508 mutation, there are hundreds of other dist…
View article: Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial Open
BACKGROUND: Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among wome…
View article: General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants Open
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Though most people with CF have one or two copies of the delF508 mutation, there are hundreds of other di…
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. Open
BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative brea…
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival Open
The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used indiv…
View article: Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response Vulnerability
Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response Vulnerability Open
Cystic Fibrosis (CF) is a lethal genetic disorder caused by variants in CF transmembrane conductance regulator (CFTR). Many variants are treatable with correctors, which enhance the folding and trafficking of CFTR. However, approximately 3…
View article: Cost-Effectiveness of Parathyroid Cryopreservation and Autotransplantation
Cost-Effectiveness of Parathyroid Cryopreservation and Autotransplantation Open
Importance Delayed autotransplantation of cryopreserved parathyroid tissue (DACP) is the only surgical treatment for permanent postoperative hypoparathyroidism. Studies suggest that only a small minority of cryopreserved samples are ultima…
View article: Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Open
Dysregulation of MAL (myelin and lymphocyte protein) has been implicated in several malignancies including esophageal, ovarian, and cervical cancers. The MAL protein functions in apical transport in polarized epithelial cells; therefore, i…
View article: Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer Open
Supplementary Figure 1 Mismatch repair dysregulation associates with high mutation load and poor clinical outcome in patients with ER breast cancer. Supplementary Figure 2 MutL complex disruption in ER breast cancer cells induces endocrine…
View article: Data from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Data from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer Open
Significant endocrine therapy–resistant tumor proliferation is present in ≥20% of estrogen receptor–positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intri…
View article: Data from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Data from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer Open
Significant endocrine therapy–resistant tumor proliferation is present in ≥20% of estrogen receptor–positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intri…
View article: Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer Open
Supplementary Figure 1 Mismatch repair dysregulation associates with high mutation load and poor clinical outcome in patients with ER breast cancer. Supplementary Figure 2 MutL complex disruption in ER breast cancer cells induces endocrine…
View article: Supplementary Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
Supplementary Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Open
Supplementary Data from Inactivation of the MAL Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
View article: Supplementary Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
Supplementary Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Open
Supplementary Data from Inactivation of the MAL Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
View article: Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy
Data from Inactivation of the <i>MAL</i> Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Open
Dysregulation of MAL (myelin and lymphocyte protein) has been implicated in several malignancies including esophageal, ovarian, and cervical cancers. The MAL protein functions in apical transport in polarized epithelial cells; therefore, i…
View article: Supplemental Figure 1 and 2 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Supplemental Figure 1 and 2 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
Supplemental Figure 1: Nuclear and cytoplasmic scoring system for cyclin E. Supplemental Figure 2: Breast cancer recurrence-free interval in patients with estrogen receptor-positive comparing positive and negative staining for Ki67
View article: Supplementary Figure 4 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Figure 4 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma Open
Supplementary Figure 4 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
View article: Supplemental Methods and Legends from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Supplemental Methods and Legends from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
The file contains supplemental methods pertaining to the supplemental figures and supplemental figure legends
View article: Supplemental Figure 1 and 2 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Supplemental Figure 1 and 2 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
Supplemental Figure 1: Nuclear and cytoplasmic scoring system for cyclin E. Supplemental Figure 2: Breast cancer recurrence-free interval in patients with estrogen receptor-positive comparing positive and negative staining for Ki67
View article: Supplementary Figures S1-S3; Tables S1, S2 from Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy
Supplementary Figures S1-S3; Tables S1, S2 from Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy Open
Supplementary Figures S1-S3; Tables S1, S2 from Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy
View article: Data from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Data from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
Purpose: Preoperative aromatase inhibitor (AI) therapy has demonstrated efficacy in hormone receptor (HR)-positive postmenopausal breast cancer. However, many patients have disease that is either intrinsically resistant to AIs or th…
View article: Supplementary Figure Legends and Methods from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Figure Legends and Methods from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma Open
Supplementary Figure Legends and Methods from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
View article: Supplemental Figure 5 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Supplemental Figure 5 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
Low molecular weight cyclin E (LMW-E) expression overcomes exemestane inhibition of proliferation
View article: Data from Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy
Data from Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy Open
Purpose: Breast cancer is a heterogeneous disease, and markers for disease subtypes and therapy response remain poorly defined. For that reason, we employed a prospective neoadjuvant study in locally advanced breast cancer to identi…
View article: Supplementary Appendix from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Appendix from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma Open
Supplementary Appendix from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
View article: Supplemental Figure 7 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Supplemental Figure 7 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer Open
LMW-E expression in tumor xenografts.